Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review

Lenvatinib plus transarterial chemoembolization (TACE)have become the first choice for patients with hepatocellular carcinoma (HCC) that are unsuitable for TACE. Sorafenib plus TACE therapy for patients with portal vein tumor thrombus (PVTT) achieved positive results. However, Lenvatinib plus TACE a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Liwei, Xu, Xuelong, Meng, Fanguang, Liu, Qian, Wang, Hankang, Li, Xiaodong, Li, Guijie, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555078/
https://www.ncbi.nlm.nih.gov/pubmed/36249023
http://dx.doi.org/10.3389/fonc.2022.980214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555078/
https://www.ncbi.nlm.nih.gov/pubmed/36249023
http://dx.doi.org/10.3389/fonc.2022.980214

Ejemplares similares